FDA requires new warnings on GLP-1 drugs over potential vision loss risk

The U.S. Food and Drug Administration announced it is requiring manufacturers of all GLP-1 drugs to add safety warnings regarding a potential increased risk of a rare eye condition known as nonarteritic anterior ischemic optic neuropathy. This condition can cause sudden vision loss and permanent impairment due to decreased blood flow to the optic nerve. The agency's decision follows a review of clinical trials, real-world patient data, and published studies. While a definitive causal relationship has not yet been established and diabetes itself is a known risk factor, the FDA identified cases among users of popular medications like Wegovy and Zepbound. Major drugmakers like Novo Nordisk and Eli Lilly responded to the update, with representatives noting they are evaluating the findings or maintaining confidence in the overall benefit-risk profile of their medicines. Analysts suggest the class-wide labeling action will draw attention but is expected to have a limited impact on overall medication use.